Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)

被引：0
|
作者：
Samalin, E. [1 ]
Bouche, O. [2 ]
Thezenas, S. [1 ]
Francois, E. [3 ]
Adenis, A. [4 ]
Bennouna, J. [5 ]
Taieb, J. [6 ]
Desseigne, F. [7 ]
Laurent-Puig, P. [6 ]
Ychou, M. [8 ]
机构：
[1] CRLC Val dAurelle, Stat, Montpellier 5, France
[2] CHU Robert Debre, Reims, France
[3] Ctr Antoine Lacassagne, F-06054 Nice, France
[4] Ctr Oscar Lambret, F-59020 Lille, France
[5] Ctr Rene Gauducheau, F-44035 Nantes, France
[6] Hop Georges Pompidou, APHP, Paris 15, France
[7] Ctr Leon Berard, F-69373 Lyon, France
[8] CRLC Val dAurelle, Oncol, Montpellier 5, France
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71736-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [41] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Salvatore, L.
    Fornaro, L.
    Baldi, G.
    Stasi, I
    Cupini, S.
    Ciarlo, A.
    Del Monte, F.
    Trenta, P.
    Mezi, S.
    Rondini, M.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 12 - 12
  • [42] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [43] Translational research with RG7160 (GA201) leads to a phase II clinical study in combination with FOLFIRI in 2nd line metastatic colorectal cancer (mCRC)
    Cervantes, Andres
    Markman, Ben
    Siena, Salvatore
    Pericay, Carles
    Aprile, Giuseppe
    Bridgewater, John
    Cubillo, Antonio
    Waterston, Ashita
    Paz Ares, Luis
    Soria, Jean-Charles
    Temam, Stephane
    Oppenheim, David
    Chick, Jon
    Carlile, David
    Golding, Sophie
    Banholzer, Maria Longauer
    Passioukov, Alexandre
    Gerdes, Chrstian
    Soehrman, Sophia
    Mancao, Christoph
    Manenti, Luigi
    Tabernero, Josep
    CANCER RESEARCH, 2012, 72
  • [44] KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Salvatore, L.
    Loupakis, F.
    Fontanini, G.
    Cremolini, C.
    Stasi, I.
    Fabbri, A.
    Ciarlo, A.
    Granetto, C.
    Basolo, F.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
  • [45] A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
    Shimoyama, Rai
    Kimura, Tetsuo
    Takaoka, Toshi
    Sakamoto, Kazuki
    Kawamoto, Shunji
    Yoshizaki, Koji
    Negoro, Yuji
    Goda, Fuminori
    Tsuji, Akihito
    Nakayama, Tsuyoshi
    Miyamoto, Hiroshi
    Takayama, Tetsuji
    Niitsu, Yoshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [46] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Salvatore, L.
    Loupakis, F.
    Cremolini, C.
    Lupi, C.
    Masi, G.
    Sensi, E.
    Stasi, I
    Fornaro, L.
    Vasile, E.
    Schirripa, M.
    Truscelli, K.
    Giannini, R.
    Baldi, G. G.
    Altavilla, A.
    Ciarlo, A.
    Granetto, C.
    Fea, E.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [47] Phase I study of gefitinib in combination with capecitabine and irinotecan for 2nd-and/or 3rd-line treatment in patients with metastatic colorectal cancer.
    Arnold, D
    Constantin, C
    Seufferlein, T
    Gahlemann, CG
    Schmoll, HJ
    Kretzschmar, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 293S - 293S
  • [48] A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.
    Pietrantonio, Filippo
    Lobefaro, Riccardo
    Antista, Maria
    Miceli, Rosalba
    Raimondi, Alessandra
    Lonardi, Sara
    Rimassa, Lorenza
    Saggio, Serena
    Capone, Iolanda
    Farina, Gabriella
    Longarini, Raffaella
    Mosconi, Stefania
    Sartore-Bianchi, Andrea
    Tomasello, Gianluca
    Perrone, Federica
    Barault, Ludovic
    Milione, Massimo
    Di Nicolantonio, Federica
    Di Bartolomeo, Maria
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC): Final results and pharmacokinetic data of a phase VIIa study.
    Folrecht, G
    Lutz, MP
    Seufferlein, T
    Schoeffski, P
    Nolting, A
    Pollert, P
    Koehne, CH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 281S - 281S
  • [50] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
12345